Last updated on November 2019

Effect of Efpeglenatide on Cardiovascular Outcomes

Brief description of study

Primary Objective:

-To demonstrate that, efpeglenatide doses 1 and 2 is noninferior to placebo on 3-point major adverse cardiac event (MACE) in Type 2 diabetes mellitus (T2DM) patients at high cardiovascular (CV) risk.

Secondary Objectives:

  • To demonstrate that efpeglenatide doses 1 and 2 is superior to placebo in T2DM patients with high CV risk on the following parameters:
  • 3-point MACE.
  • Expanded CV outcome.
  • Composite outcome of new or worsening nephropathy.
  • To assess the safety and tolerability of efpeglenatide doses 1 and 2, both added to standard of care in T2DM patients at high CV risk.

Detailed Study Description

The estimated study duration per participant is up to approximately 36 months.

Clinical Study Identifier: NCT03496298

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.